isomitraphylline: isolated from Uncaria tomentosa
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Uncaria tomentosa | species | [no description available] | Rubiaceae | The Madder plant family of the order Gentianales (formerly Rubiales), subclass Asteridae, class Magnoliopsida includes important medicinal plants that provide QUININE; IPECAC; and COFFEE. They have opposite leaves and interpetiolar stipules.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 11726520 |
SCHEMBL ID | 23259271 |
MeSH ID | M0496837 |
Synonym |
---|
4963-01-3 |
isomitraphylline |
7-isomitraphylline |
isomitraphyllin |
isomitraphylline (constituent of cat's claw) [dsc] |
unii-xkc69mv51v |
ajmalicine oxindole a |
xkc69mv51v , |
formosanan-16-carboxylic acid, 19-methyl-2-oxo-, methyl ester, (7alpha,19alpha)- |
formosanan-16-carboxylic acid, 19-methyl-2-oxo-, methyl ester, (7.alpha.,19.alpha.)- |
(1's,3s,4a's,5a's,10a'r)-methyl 1'-methyl-2-oxo-1',4a',5',5a',7',8',10',10a'-octahydrospiro[indoline-3,6'-pyrano[3,4-f]indolizine]-4'-carboxylate |
Q27293881 |
SCHEMBL23259271 |
HY-120720 |
E88914 |
methyl (1s,4as,5as,6s,10ar)-1-methyl-2'-oxospiro[1,4a,5,5a,7,8,10,10a-octahydropyrano[3,4-f]indolizine-6,3'-1h-indole]-4-carboxylate |
CS-0078903 |
isomitraphylline (constituent of cat's claw) |
AKOS040761901 |
FS-6908 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.29) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |